TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›DMAAR
DMAAR logo

DMAAR

Drugs Made In America Acquisition Corp.

Next earnings Aug 3, 2026

Avoid
$0.11
▲ +9.43%
$0.11▼ -4.41%
over 1Y
L $0.04H $0.23
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+9.4%
1W+9.4%
1M-4.2%
3M+91.5%
YTD-28.2%
1Y-4.4%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
F
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Long (>12mo)

Pre-deal Cayman blank-check SPAC with no business, negative equity, and no announced target — a bet on a merger that may never come.

Price $0.11 · latest

DMAAR is not an operating company — it is a Cayman Islands blank-check SPAC incorporated May 23, 2024 that, in its own words, has 'neither engaged in any operations nor generated any operating revenues to date.' The FY2025 'net income' of $5.94M is an accounting artifact: $8.76M of interest earned on the ~$231.15M trust account, offset by $2.82M of G&A that itself includes a $2.0M non-cash share-issuance expense (200,000 shares handed to a sponsor investor for no consideration). Operating income is actually -$2.82M and operating cash flow is -$539K. There is no revenue line and, per the filing, none is expected until a business combination closes. This is a shell whose entire value proposition is a deal that has not been announced.

The balance sheet reads alarmingly on the surface — stockholders' equity of -$7.26M against $240M of assets — but that is standard SPAC optics: the ~$231M of redeemable trust shares sit outside permanent equity, and $6.9M of deferred underwriting fees plus other accruals drive the $7.28M of liabilities. Operating cash is a rounding error at $6,137. So the company itself is solvent only via the trust; the public equity holder's claim is essentially the ~$10.00/share redemption value in trust, NOT the reported book equity.

Is DMAAR a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bear put spread (caution)~90d expiry
  • Long put 0 @ ~0.00 est
  • Short put 0 @ ~0.00 est
debit $0max +$0max $0

AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY25
Revenue—
Gross profit—
Operating income-$2.82M
Net income$5.94M
Diluted EPS—
Net margin—

10-year statements — income, cash flow, balance sheet & CSV export →

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.83M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield323.9%
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash$6.14K

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 10-Q Quarterly report2026-05-14

    Q1'26: still a shell earning trust interest, no target closed yet

  2. 8-K Material agreement2026-05-05

    Entered a new material definitive agreement (Item 1.01)

  3. 8-K Charter / bylaws change2026-05-01

    Shareholder vote: charter amendment/extension approved to keep SPAC alive

  4. 8-K Material agreement2026-04-28

    Signed another material definitive agreement (Item 1.01)

  5. 10-K Annual report2026-04-15

    FY25 net income $5.9M on trust interest; no target, going-concern risk

  6. DEF 14A Proxy statement2026-04-14

    Proxy for shareholder meeting, likely combination-deadline extension

  7. 8-K Other event2026-04-08

    Disclosed an other-events update (Item 8.01)

  8. NT 10-K Late filing notice2026-04-01

    Notified SEC the annual 10-K would be filed late

  9. 8-K Material agreement2026-03-27

    New agreement plus a direct financial obligation (loan/note) incurred

Recent filings

all on EDGAR ↗
SCHEDULE 13GFiling2026-06-26open ↗10-QPeriod ending 2026-03-312026-05-14open ↗SCHEDULE 13GFiling2026-05-14open ↗425Filing2026-05-05open ↗8-KPeriod ending 2026-04-292026-05-05open ↗8-KPeriod ending 2026-04-272026-05-01open ↗8-KPeriod ending 2026-04-222026-04-28open ↗DEFR14AFiling2026-04-16open ↗10-KPeriod ending 2025-12-312026-04-15open ↗DEF 14APeriod ending 2026-04-272026-04-14open ↗8-KPeriod ending 2026-04-072026-04-08open ↗NT 10-KPeriod ending 2025-12-312026-04-01open ↗

Quality score

F
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial healthF
Momentum—
  • ✓Profitable (positive net income)
  • ✓Liabilities below 2× equity
0.0052-week0.00
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

Net income$5.94M
Operating income-$2.82M
Cash & equivalents$6.14K+354.3%
Total assets$240M+43456.4%
Total liabilities$7.28M+814.5%
Stockholders' equity-$7.26M-2866.8%
L/E: -1.00x

Frequently asked

Is Drugs Made In America Acquisition Corp. (DMAAR) a buy?
DMAAR currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Pre-deal Cayman blank-check SPAC with no business, negative equity, and no announced target — a bet on a merger that may never come.
What is Drugs Made In America Acquisition Corp.'s quality score?
DMAAR scores 36.666666666666664/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0002028614, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/4/2026, 10:34:53 AM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:34 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2025-02-18
Drugs Made In America Acquisition LLC
10% owner
Buy30.0K
2025-02-18
Stockwell Lynn
CEO and Exe. Chair of Board
Buy30.0K
2025-01-29
Drugs Made In America Acquisition LLC
10% owner
Buy400K
2025-01-29
Drugs Made In America Acquisition LLC
10% owner
Disposed (J)400K
2025-01-29
Drugs Made In America Acquisition LLC
10% owner
Sell5.70M
2025-01-29
Stockwell Lynn
CEO and Executive COB
Buy400K
2025-01-29
Stockwell Lynn
CEO and Executive COB
Disposed (J)400K
2025-01-29
Stockwell Lynn
CEO and Executive COB
Sell5.70M
2025-01-29
Shulgan Myron W.
Director
Acquired (J)100K
2025-01-29
Prasad Sridhar G.
Director
Acquired (J)100K
2025-01-29
Do Catherine
Director
Acquired (J)100K
2025-01-29
Worman Glenn C.
CFO
Acquired (J)100K

Recent news

market news →
Tuesday's session: top gainers and losersBullish
chartmill.com· 2025-09-16
Let's take a look at the stocks that are in motion in today's session.Bullish
chartmill.com· 2025-09-16

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score37 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2